High Blood Pressure Medicines Show Promise For Treating Heart Disease

Press Release  |  www.prnewswire.com | Oct 19, 2009

However, the drugs have risks of their own. Risks associated with ACE inhibitors include a persistent cough, sudden fainting, too much potassium in the blood, and dangerously low blood pressure (hypotension).

http://www.prnewswire.com/news-releases/high-blood-pressure-medicines-show-promise-for-treating-heart-disease-64827362.html

Medical News: FDA Expands Telmisartan Indications - in Product Alert, Prescriptions from MedPage

Press Release  |  www.medpagetoday.com | Oct 19, 2009

WASHINGTON -- The FDA has expanded the indication for the antihypertension drug telmisartan (Micardis), making it the first angiotensin receptor blocker (ARB) approved for primary prevention in patien

http://www.medpagetoday.com/ProductAlert/Prescriptions/16498

Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure

Press Release  |  news.prnewswire.com | Sep 17, 2009

"This unique combination brings together the powerful blood pressure lowering effects of valsartan and aliskiren," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division.

http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/09-17-2009/0005096263&EDATE=

Expedition to Mount Everest offers new insights into chronic disease

Press Release  |  www.pharmiweb.com | Jun 23, 2009

News and press releases from the pharmaceutical industry. Comprehensive news coverage for the pharmaceutical sector from PharmiWeb.com

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=6973

Drug Treatment for Marfan Syndrome Looks Promising, Johns Hopkins Researchers Say

Press Release  |  www.hopkinsmedicine.org | Apr 23, 2009

A small study in 18 patients assessing the effectiveness of the drug losartan for treating Marfan syndrome in children has yielded encouraging results. Reporting in the June 26 issue of The New England Journal of Medicine, Johns Hopkins researchers showed that losartan-a compound used for years to

http://www.hopkinsmedicine.org/Press_releases/2008/06_25_08.html

[Therapeutics] Review: less than maximum doses of ACE inhibitors lower BP to near maximum levels in hypertension

Press Release  |  ebm.bmj.com | Mar 30, 2009

In patients with primary hypertension, what is the dose-related efficacy of angiotensin converting enzyme (ACE) inhibitors for lowering blood pressure (BP)?

http://ebm.bmj.com/cgi/content/short/14/2/49?rss=1

The Arginine Salt of Coversyl and Coversyl Plus Will Replace the Tert-Butylamine Salt of These Products

Press Release  |  www.prweb.com | Apr 10, 2008

PR: French drugs research company Servier, whose UK headquarters are at Wexham Springs in Berkshire, has announced that as of 1 April 2008 the arginine salt will replace the tert-butylamine salt of Coversyl and Coversyl Plus. Wexam Springs, Berkshire (PRWEB) April 10

http://www.prweb.com/releases/2008/04/prweb840594.htm

Teva News and PR

Jerusalem, Israel, August 23, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the U.S. FDA final approval to manufacture and market Enalapril Maleate 2.5, 5, 10 and 20mg Tablets.

http://www.tevapharm.com/pr/2000/pr_267.asp

bmj.com -- Press Releases

You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

http://www.bmj.com/content/vol324/issue7339/press_release.dtl

Press Releases

MARIETTA, Ga. and PALO ALTO, Calif., Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) and Solvay Pharmaceuticals, Inc.

http://www.cvt.com/PressRelease.aspx?releaseID=650814